In developing countries rotavirus is the leading cause of severe diarrhoea and diarrhoeal deaths in children under 5. Vaccination could greatly alleviate that burden, but in Mexico as in most low- and middle-income countries the decision to add rotavirus vaccine to the national immunisation program will depend heavily on its cost-effectiveness and affordability. The objective of this study was to assess the cost-effectiveness of including the pentavalent rotavirus vaccine in Mexico's national immunisation program.
Division of Health Economics, National Institute of Public Health, Av Universidad No 655, Col Santa María Ahuacatitlán, Cuernavaca, Morelos, 62508, México. avalencia@correo.insp.mx
